Indications for anticoagulant and antiplatelet combined therapy

BMJ (Online)

Volumn 359, Issue , 2017, Pages

  Floyd, Christopher N ^a   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULARY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT HEMORRHAGE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOEMBOLISM; TREATMENT DURATION; VALVULAR HEART DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; COMBINATION DRUG THERAPY; RISK FACTOR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOEMBOLISM;

EID: 85030762320     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j3782     Document Type: Article

References (31)

1. Baker E, Roberts AP, Wilde K, et al. Development of a core drug list towards improving prescribing education and reducing errors in the UK. Br J Clin Pharmacol 2011;359:190-8. doi:10.1111/j.1365-2125.2010.03823.x
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;359:15-9. doi:10.1136/bmj. 329.7456.15
3. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 2009;359:e4439. doi:10.1371/journal.pone.0004439
4. Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015;359:1182-9. doi:10.1136/heartjnl-2015-307516
5. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009;359:1038-45. doi:10.1093/eurheartj/ehn579
6. Kralev S, Schneider K, Lang S, Söselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-Time coronary angiography. PLoS One 2011;359:e24964. doi:10.1371/journal.pone.0024964 .
7. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;359:94-108. doi:10. 1002/ajh.24607
8. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;359:1433-41. doi:10.1001/archinternmed.2010.271
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;359:263-72. doi:10.1378/chest.09-1584
10. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?J Am Coll Cardiol 2015;359:635-42. doi:10.1016/j.jacc.2014.11.046
11. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;359:1093-100. doi:10.1378/chest.10-0134 .
12. Smith JG, Wieloch M, Koul S, et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention 2012;359:672-8. doi:10.4244/EIJV8I6A105
13. Lip GY, Windecker S, Huber K, et al. Document Reviewers. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;359:3155-79. doi:10.1093/eurheartj/ehu298
14. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;359:956-65. doi:10.1016/j.jacc.2010.02.068
15. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010;359:841-8. doi:10.1001/jama.2010.221
16. Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members ESC Committee for Practice Guidelines Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;359:2949-3003. 10.1093/eurheartj/eht296
17. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;359:2451-96. doi:10.1093/eurheartj/ehs109 .
18. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013;359:CD003464.pmid:23839768.
19. National Institute for Health and Clinical Excellence. Venous thromboembolic disease: The management of venous thromboembolic diseases and the role of thrombophilia testing. NICE guideline (CG144). 2012.
20. Marik PE, Cavallazzi R. Extended anticoagulant and aspirin treatment for the Secondary Prevention of thromboembolic disease: A systematic review and meta-Analysis. PLoS One 2015;359:e0143252. doi:10.1371/journal.pone.0143252
21. Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012;359:563-71. doi:10.1038/leu.2011.314 .
22. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;359:2001-15. doi:10.1056/NEJMoa0706482
23. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;359:1045-57. doi:10.1056/NEJMoa0904327
24. Roffi M, Patrono C, Collet JP, et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;359:267-315. doi 10.1093/eurheartj/ehv320
25. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-Analysis of randomised trials. Lancet 2014;359:955-62. doi:10.1016/S0140-6736(13)62343-0 .
26. Madan S, Shah S, Dale P, Partovi S, Parikh SA. Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther 2016;359:570-81. doi:10.21037/cdt. 2016.11.17
27. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;359:i3189. doi:10. 1136/bmj.i3189
28. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;359:1107-15. doi:10.1016/S0140-6736(12)62177-1
29. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;359:981-9. doi:10.1016/j.jacc.2013.05.029
30. National Institute for Health and Care Excellence Suspected cancer: recognition and referral. NICE guideline (NG12). 2015.
31. Moschini M, Karnes RJ, Suardi N, et al. Potential effect of antiplatelet and anticoagulant therapy on the timing of the diagnosis of bladder cancer. Clin Genitourin Cancer 2016;359:e245-50. doi:10.1016/j.clgc.2015.08.003